Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit
During the showcase, Merakris CEO Chris Broderick presented MTX-001, a first-in-class injectable biologic drug therapy derived from purified amniotic fluid for the treatment of non-healing venous leg ulcers (VLUs) including:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
34 minutes ago
- Toronto Star
OTC Markets Group Welcomes First Phosphate Corp. to OTCQX
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced First Phosphate Corp. (CSE: PHOS; OTCQX: FRSPF), an igneous phosphate mineral development company for the LFP battery industry, has qualified to trade on the OTCQX® Best Market. First Phosphate Corp. upgraded to OTCQX from the OTCQB® Venture Market. First Phosphate Corp. begins trading today on OTCQX under the symbol 'FRSPF.' U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on
Toronto Star
34 minutes ago
- Toronto Star
CPA compensation hits record high, outpaces inflation
TORONTO, Aug. 12, 2025 (GLOBE NEWSWIRE) — Canadian Chartered Professional Accountants (CPAs) are earning more than ever before, with compensation growth outpacing inflation and doubling that of the broader workforce, according to new data from CPA Canada. The 2025 CPA Compensation Study, conducted by Leger, reports CPAs earned a national median compensation of $154,000 in 2024—the highest since the study began in 2012. This marks a 47 per cent increase over 12 years, highlighting the enduring demand and relevance of the CPA designation across a changing economic landscape.
Toronto Star
34 minutes ago
- Toronto Star
UNISYNC Reports Q3 Fiscal 2025 Operating Results Showing Continued Improvement in Profitability
TORONTO, Aug. 12, 2025 (GLOBE NEWSWIRE) — Unisync Corp. ('Unisync') (TSX:'UNI') (OTC:'USYNF') today announced strong operating results for the three months ended June 30, 2025, highlighted by continued profitability, significant gross margin gains, and disciplined cost management. For the quarter, Unisync delivered net income before tax of $1.8 million ($0.10 per share) and Adjusted EBITDA of $3.5 million ($0.18 per share) on revenues of $21.9 million. This marks a substantial improvement from the prior year's net loss before tax of $1.2 million and Adjusted EBITDA of $1.1 million.
